Skip to main content

Volume 2 Supplement 3

Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)

Wnt pathway activation functionally reprograms human antigen-specific T cells

Polyfunctionality is a hallmark of protective immunity, yet the molecular mechanisms governing polyfunctional T cells are poorly understood. After TCR activation, naïve CD8+ T cells undergo proliferation and differentiation, which lead to effector functions and memory subset development. However only a portion of activated T cells develop into memory CD8+ T cells and with chronic stimulation become terminally differentiated and exhausted CD8+ T cells, as defined by CCR7-/CD45RA+, and functionally impair effective immune responses [1]. We therefore probed the ability to reverse terminally differentiated antigen-specific cells using pharmacological agents. Stimulating human memory CD8+ T cells with cognate TCR stimulation in the presence of Wnt agonist enhances polyfunctionality and stemness. Both M1-influenza+ and CMV+ CD8+ T cell responses were reprogrammed and revealed sustained effects from initial Wnt pathway activation in vitro. Future work with cancer antigens and reprogramming of differentiated CD8+ responses could lead to improved in vitro culture conditions for adoptive immunotherapy.


  1. 1.

    Seder R, Darrah P, Roederer M: T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008, 8: 247-258. 10.1038/nri2274.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Catherine Bessell.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chiu, Y., Sung, B., Bessell, C. et al. Wnt pathway activation functionally reprograms human antigen-specific T cells. j. immunotherapy cancer 2, P4 (2014).

Download citation


  • Effector Function
  • Protective Immunity
  • Human Memory
  • Cancer Antigen
  • Adoptive Immunotherapy